532 related articles for article (PubMed ID: 24342950)
21. Minimal residual disease quantification in childhood acute lymphoblastic leukemia by real-time polymerase chain reaction using the SYBR green dye.
Li AH; Forestier E; Rosenquist R; Roos G
Exp Hematol; 2002 Oct; 30(10):1170-7. PubMed ID: 12384148
[TBL] [Abstract][Full Text] [Related]
22. MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR.
Pott C; Brüggemann M; Ritgen M; van der Velden VH; van Dongen JJ; Kneba M
Methods Mol Biol; 2013; 971():175-200. PubMed ID: 23296964
[TBL] [Abstract][Full Text] [Related]
23. Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia.
Donovan JW; Ladetto M; Zou G; Neuberg D; Poor C; Bowers D; Gribben JG
Blood; 2000 Apr; 95(8):2651-8. PubMed ID: 10753847
[TBL] [Abstract][Full Text] [Related]
24. Minimal residual disease detection using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: Slovak experience.
Kolenova A; Hikkel I; Ilencikova D; Hikkelova M; Sejnova D; Kaiserova E; Cizmar A; Puskacova J; Bubanska E; Oravkinova I; Gencik M
Neoplasma; 2010; 57(6):552-61. PubMed ID: 20845994
[TBL] [Abstract][Full Text] [Related]
25. Minimal residual disease (MRD) detection using rearrangement of immunoglobulin/T cell receptor genes in adult patients with acute lymphoblastic leukemia (ALL).
Shahkarami S; Mehrasa R; Younesian S; Yaghmaie M; Chahardouli B; Vaezi M; Rezaei N; Nikbakht M; Alimoghaddam K; Ghavamzadeh A; Tavakkoly-Bazzaz J; Ghaffari SH
Ann Hematol; 2018 Apr; 97(4):585-595. PubMed ID: 29392424
[TBL] [Abstract][Full Text] [Related]
26. Cloned IGH VDJ targets as tools for personalized minimal residual disease monitoring in mature lymphoid malignancies; a feasibility study in mantle cell lymphoma by the Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang.
Gimenez E; Chauvet M; Rabin L; Puteaud I; Duley S; Hamaidia S; Bruder J; Rolland-Neyret V; Le Gouill S; Tournilhac O; Voog E; Maisonneuve H; Jacob MC; Leroux D; Béné MC; Formisano-Tréziny C; Gabert J; Gressin R; Callanan MB
Br J Haematol; 2012 Jul; 158(2):186-197. PubMed ID: 22626453
[TBL] [Abstract][Full Text] [Related]
27. Comparative analysis between RQ-PCR and digital-droplet-PCR of immunoglobulin/T-cell receptor gene rearrangements to monitor minimal residual disease in acute lymphoblastic leukaemia.
Della Starza I; Nunes V; Cavalli M; De Novi LA; Ilari C; Apicella V; Vitale A; Testi AM; Del Giudice I; Chiaretti S; Foà R; Guarini A
Br J Haematol; 2016 Aug; 174(4):541-9. PubMed ID: 27172403
[TBL] [Abstract][Full Text] [Related]
28. Utility of Measurable Residual Disease (MRD) Assessment in Mantle Cell Lymphoma.
Wu S; Blombery P; Westerman D; Tam CS
Curr Treat Options Oncol; 2023 Aug; 24(8):929-947. PubMed ID: 37249800
[TBL] [Abstract][Full Text] [Related]
29. [Assessment of minimal residual disease in adult patients with B-lineage acute lymphoblastic leukemia using rearranged immunoglobulin loci detection].
Yao L; Chen ZX; Cen JN; Liu H; He J; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2010 Jul; 31(7):433-7. PubMed ID: 21122394
[TBL] [Abstract][Full Text] [Related]
30. Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network.
Della Starza I; Cavalli M; De Novi LA; Genuardi E; Mantoan B; Drandi D; Barbero D; Ciabatti E; Grassi S; Gazzola A; Mannu C; Agostinelli C; Piccaluga PP; Bomben R; Degan M; Gattei V; Guarini A; Foà R; Galimberti S; Ladetto M; Ferrero S; Del Giudice I;
Hematol Oncol; 2019 Oct; 37(4):368-374. PubMed ID: 31325190
[TBL] [Abstract][Full Text] [Related]
31. Minimal residual disease detection by next-generation sequencing of different immunoglobulin gene rearrangements in pediatric B-ALL.
Chen H; Gu M; Liang J; Song H; Zhang J; Xu W; Zhao F; Shen D; Shen H; Liao C; Tang Y; Xu X
Nat Commun; 2023 Nov; 14(1):7468. PubMed ID: 37978187
[TBL] [Abstract][Full Text] [Related]
32. Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1.
Short NJ; Jabbour E; Macaron W; Ravandi F; Jain N; Kanagal-Shamanna R; Patel KP; Loghavi S; Haddad FG; Yilmaz M; Issa GC; Kebriaei P; Kornblau SM; Pelletier S; Flores W; Matthews J; Garris R; Kantarjian H
Am J Hematol; 2023 Aug; 98(8):1196-1203. PubMed ID: 37183966
[TBL] [Abstract][Full Text] [Related]
33. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.
van der Velden VH; Hochhaus A; Cazzaniga G; Szczepanski T; Gabert J; van Dongen JJ
Leukemia; 2003 Jun; 17(6):1013-34. PubMed ID: 12764363
[TBL] [Abstract][Full Text] [Related]
34. [Detection of minimal residual disease in childhood acute lymphoblastic leukemia by using real-time quantitative PCR].
Zhang YT; Luo ZF; Fang JP; Guo HX; Huang K; Li CK
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1235-9. PubMed ID: 21129267
[TBL] [Abstract][Full Text] [Related]
35. Next-generation sequencing of PTEN mutations for monitoring minimal residual disease in T-cell acute lymphoblastic leukemia.
Germano G; Valsecchi MG; Buldini B; Cazzaniga G; Zanon C; Silvestri D; Te Kronnie G; Basso G; Paganin M
Pediatr Blood Cancer; 2020 Jan; 67(1):e28025. PubMed ID: 31571345
[TBL] [Abstract][Full Text] [Related]
36. High-throughput sequencing of immunoglobulin heavy chain for minimal residual disease detection in B-lymphoblastic leukemia.
Correia RP; Puga RD; Muto NH; Lee MLM; Torres DC; Hassan R; Bacal NS; Hamerschlak N; Campregher PV
Int J Lab Hematol; 2021 Aug; 43(4):724-731. PubMed ID: 33393719
[TBL] [Abstract][Full Text] [Related]
37. MRD detection in acute lymphoblastic leukemia patients using Ig/TCR gene rearrangements as targets for real-time quantitative PCR.
van der Velden VH; van Dongen JJ
Methods Mol Biol; 2009; 538():115-50. PubMed ID: 19277574
[TBL] [Abstract][Full Text] [Related]
38. Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting.
van der Velden VH; Panzer-Grümayer ER; Cazzaniga G; Flohr T; Sutton R; Schrauder A; Basso G; Schrappe M; Wijkhuijs JM; Konrad M; Bartram CR; Masera G; Biondi A; van Dongen JJ
Leukemia; 2007 Apr; 21(4):706-13. PubMed ID: 17287857
[TBL] [Abstract][Full Text] [Related]
39. Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study.
Cheminant M; Derrieux C; Touzart A; Schmit S; Grenier A; Trinquand A; Delfau-Larue MH; Lhermitte L; Thieblemont C; Ribrag V; Cheze S; Sanhes L; Jardin F; Lefrère F; Delarue R; Hoster E; Dreyling M; Asnafi V; Hermine O; Macintyre E
Haematologica; 2016 Mar; 101(3):336-45. PubMed ID: 26703963
[TBL] [Abstract][Full Text] [Related]
40. Next-generation sequencing-based MRD in adults with ALL undergoing hematopoietic cell transplantation.
Liang EC; Dekker SE; Sabile JMG; Torelli S; Zhang A; Miller K; Shiraz P; Hayes-Lattin B; Leonard JT; Muffly L
Blood Adv; 2023 Jul; 7(14):3395-3402. PubMed ID: 37196642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
